Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone : analyses from the Phase II HORIZON study
Larocca, Alessandra (Azienda Ospedaliero - Universitaria Città della Salute e della Scienza)
Leleu, Xavier (CHU de Poitiers)
Touzeau, Cyrille (Université d'Angers)
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer)
Paner, Agne (Rush University Medical Center)
Mateos, M. V (Instituto de Investigación Biomédica de Salamanca)
Cavo, Michele (Bologna University School of Medicine)
Maisel, Christopher (Baylor Scott & White Charles A)
Alegre, Adrian (Hospital Universitario de la Princesa (Madrid))
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras)
Raptis, Anastasios (niversity of Pittsburgh School of Medicine)
Rodriguez-Otero, Paula (Clínica Universidad de Navarra)
Mazumder, Amitabha (The Oncology Institute of Hope and Innovation)
Laubach, Jacob (Harvard Medical School)
Nadeem, Omar (Harvard Medical School)
Sandberg, Anna (Oncopeptides AB (Suècia))
Orre, Marie (Oncopeptides AB (Suècia))
Torrång, Anna (SDS Life Science (Suècia))
Bakker, Nicolaas A (Oncopeptides AB)
Richardson, Paul G.. (Harvard Medical School)
Universitat Autònoma de Barcelona

Data:	2022
Resum:	Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health-related quality of life (HRQoL) in patients with RRMM. Assessment of patient reported-outcome measures from the pivotal, Phase II HORIZON study (OP-106; NCT02963493) in patients with RRMM (n = 64) demonstrated that melphalan flufenamide (melflufen) plus dexamethasone treatment preserved HRQoL. Patients had clinically meaningful improvements, even after eight treatment cycles, in relevant scales such as global health status/QoL, physical functioning, emotional functioning, pain, and fatigue. Patients with triple-class-refractory disease (n = 50) displayed similar improvements. Patient-reported outcome deterioration was delayed for a substantial amount of time in patients who experienced a response to melflufen plus dexamethasone treatment relative to patients who did not experience a response. These findings support the notion that treatment with melflufen plus dexamethasone may sustain or improve HRQoL over time in patients with RRMM, including in patients with triple-class-refractory disease for whom outcomes are generally worse. The clinical benefits observed in patients from the HORIZON trial are encouraging and supportive of translation into real-world practice.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols ; Biomarkers, Tumor ; Dexamethasone ; Female ; Humans ; Male ; Melphalan ; Middle Aged ; Multiple Myeloma ; Neoplasm Grading ; Neoplasm Staging ; Patient Reported Outcome Measures ; Treatment Outcome
Publicat a:	British Journal of Haematology, Vol. 196 Núm. 3 (february 2022) , p. 639-648, ISSN 1365-2141

DOI: 10.1111/bjh.17887
PMID: 34671975

10 p, 306.4 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP) > Institut de Recerca contra la Leucèmia Josep Carreras
Articles > Articles de recerca
Articles > Articles publicats